30 results about "Combining vaccines" patented technology

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

The disclosure provides a hybrid protocol for identifying and quantitating viable Eimeria oocysts, such as in a mixed industrial scale vaccine sample. The hybrid protocol comprises the combination of a volumetric viability assessment, which allows for quantifying the number of viable oocysts, and a digital PCR (dPCR) assay, which allows for quantitative determination of the species composition of a mixed sample.

The invention discloses a mixed vaccine for preventing influenza and novel coronavirus infections. As a mixed vaccine for vaccination against influenza and novel coronavirus, a whole virus inactivated vaccine obtained by inactivating virus particles of influenza virus and novel coronavirus is used, whereby a neutralizing antibody against each virus is induced without affecting the effect of each vaccine. And a defense effect is obtained for attack of each virus. In addition, the mixed vaccine based on the combination shows a good neutralizing antibody induction and virus attack defense effect even if an adjuvant is not added.

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

The invention discloses a modular combined vaccine soluble microneedle patch based on a mechanical interlocking tenon-and-mortise structure as well as a preparation method and application of the modular combined vaccine soluble microneedle patch. According to the combined and spliced micro-needle vaccine patch designed by the invention, synchronous delivery of various vaccines is realized by virtue of a micro-needle technology through fragmented loading and mechanical interlocking'mortise and tenon 'structural design, mutual interference among different vaccines is reduced at the same time, efficient protection can be provided for groups needing multi-vaccine protection by virtue of one-time inoculation, the number of inoculants is reduced, and the immune procedure is simplified; vaccine hesitation is reduced, and inoculation rate is increased; meanwhile, the biosoluble material of the microneedle structure can quickly release antigens in the skin to stimulate immune cells to aggregate so as to enhance the immune effect; the micron-sized needle array (lt; 500 m) acts on the superficial layer of the skin, is painless and can be designed into a self-adhesive patch, so that the inoculation compliance is improved; single-dose inoculation can also reduce medical cost, is suitable for resource-deficient regions, improves accessibility and burdenability, and accelerates establishment of a population immune barrier.

The application discloses a competitive ELISA detection method for Hib polysaccharide in an aluminum-containing adjuvant vaccine, and specifically, the method comprises the following steps: enzyme label plate preparation: coating Hib stock solution or PRP derivative on an enzyme label plate to prepare an enzyme label plate required for ELISA reaction; aluminum adsorption Hib sample treatment: blocking aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples with BSA, respectively, and then diluting the aluminum adjuvant adsorbed Hib reference and aluminum adjuvant combined vaccine samples after blocking; ELISA detection: adding the diluted aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples into the enzyme label plate, respectively, and then adding Hib specific antibody, generating ELISA signals through enzyme label antibody catalysis of substrates, establishing a mathematical relationship between absorbance and Hib polysaccharide content, and quantitatively calculating the Hib polysaccharide content in the aluminum adjuvant containing vaccine sample.

The invention relates to the field of biological medicine, and particularly discloses an RSV-influenza combined vaccine and application thereof. The RSV-influenza combined vaccine comprises a respiratory syncytial virus mRNA vaccine and an influenza vaccine, the respiratory syncytial virus mRNA vaccine also comprises lipid nanoparticles, and the mRNA is loaded in the lipid nanoparticles. The RSV-influenza combined vaccine is used for preventing infection of various respiratory viruses (RSV virus and influenza virus), and the LNP adjuvant of the RSV mRNA vaccine can greatly increase the immune response of the influenza vaccine and enhance the protection efficiency of the influenza vaccine in immunocompromised people.

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

The invention provides a combined vaccine based on Th1 / Th2 immune dynamic equilibrium as well as a preparation method and application of the combined vaccine. Subcutaneous delivery of interleukin 12 (IL12) and antigen (such as ovalbumin OVA) mRNA is adopted in the early stage of tumor occurrence, so that specific antigen recognition and T cell immune response of an organism are activated; when immune response enters a function decline stage, the tumor microenvironment is regulated through intratumor delivery of interleukin 4 (IL4) mRNA, the metabolic activity of T cells is maintained, and the depletion of the T cells is delayed. Through space (subcutaneous / intra-tumor) and time (early stage / middle stage) separated delivery of different immune factors, 'start-steady state maintenance 'type immune stylization regulation and control are realized, antigen-specific CTL reaction and persistent anti-tumor effect are remarkably enhanced, and the problem of immune bias caused by independent use of the antigen-specific CTL reaction and the persistent anti-tumor effect is solved.

The invention relates to the field of preparation of poultry vaccines, in particular to a preparation method of a chicken newcastle disease and avian influenza combined vaccine, which comprises the following steps: respectively inoculating susceptible chick embryos with Newcastle disease virus, infectious bronchitis virus and avian influenza virus, and harvesting infected chick embryo liquid to obtain first virus liquid, second virus liquid and third virus liquid; inoculating the susceptible duck embryo with the egg drop syndrome virus, and harvesting infected duck embryo liquid to obtain a fourth antigen; and concentrating the harvested first virus liquid, second virus liquid, third virus liquid and fourth antigen, inactivating, and mixing and emulsifying with an adjuvant. The vaccine prepared by the invention does not generate any adverse reaction to chickens, is high in experimental safety, can induce high-level neutralizing antibodies in immunized chickens, and can effectively reduce the incidence of Newcastle disease virus, infectious bronchitis virus, egg drop syndrome and avian influenza.

The application discloses an influenza virus universal and coronavirus combined polypeptide and application of a vaccine thereof, and belongs to the technical field of vaccine preparation. The vaccine is an artificial synthetic vaccine, has the characteristics of easy preparation, small toxicity, low cost, high titer, broad spectrum and conservation, and solves the complicated process of obtaining a vaccine by amplification transformation in the prior art, and improves the preparation efficiency and application efficiency. A combined polypeptide vaccine component having immunoprotection for multiple subtypes of influenza viruses and coronaviruses is designed for influenza viruses and novel coronaviruses, and Montanide ISA51 is used as an adjuvant. After mice immunized with the vaccine are infected with influenza viruses by nose dropping, it is shown that the vaccine immunization has a protective effect on mice adapted strains of influenza A H1N1 and H7N9 viruses, the combined vaccine composed of the screened six polypeptides has a protective effect on multiple influenza viruses, and has the potential to resist coronaviruses.

The invention provides an application of a chicken-derived antiviral protein in a combined vaccine of H9N2 subtype avian influenza and Newcastle disease. An immunopotentiator is the chicken-derived antiviral protein IFITM1. According to the scheme, the chicken-derived antiviral protein IFITM1 serving as an immunopotentiator is matched with the H9N2 subtype avian influenza and Newcastle disease bivalent inactivated vaccine for immunization, immunized chickens can be induced to generate a higher-level H9N2 subtype avian influenza and Newcastle disease serum HI antibody, and the detoxification inhibition effect is improved. And 21 days after the antiviral protein IFITM1 is used as an immunopotentiator and is independently inoculated under the neck and subcutaneously, the detoxification of the chicken H9N2 subtype avian influenza virus and the Newcastle disease virus can be effectively inhibited, so that the chicken tissue injury condition is obviously reduced. At present, no poultry antiviral protein immunopotentiator inactivated vaccine appears on the market in China, and the poultry immunopotentiator provided by the scheme can more effectively prevent and control the avian influenza and the Newcastle disease by preparing the H9N2 subtype avian influenza and Newcastle disease bivalent inactivated vaccine, and can make up the vacancy of the current poultry market immunopotentiator at the same time.

The present invention discloses a combination vaccine for preventing hand, foot and mouth disease, comprising inactivated enterovirus 71 and inactivated coxsackievirus group A type 16. The present invention also discloses a method for preparing the combination vaccine, which exhibits excellent adsorption efficacy and stability. The multiple antigens described above do not interfere with each other's antigenicity or immune effects after immunization, resulting in excellent immunogenicity and safety. The use of the combination vaccine can significantly simplify the vaccination process, improve vaccination efficiency, and reduce costs.

The present invention discloses a novel coronavirus combined vaccine and its preparation method. The combined vaccine comprises the following antigenic components: a recombinant novel coronavirus RBD protein, hemagglutinin from an H1N1 influenza virus strain, hemagglutinin from an H3N2 influenza virus strain, hemagglutinin from a BY influenza virus strain, and hemagglutinin from a BV influenza virus strain. The novel coronavirus combined vaccine provided by the present invention has good compatibility of antigenic components, good immunogenicity, a low aluminum adjuvant content, low safety risks, is amenable to large-scale production, is highly compatible with viral mutations, and has promising application prospects.

The application relates to the technical field of bioengineering, and discloses a porcine epidemic diarrhea mRNA vaccine and a preparation method thereof, which comprises an mRNA sequence encoding the amino acid sequence of S protein of GIIa, GIIb and GIIc type porcine epidemic diarrhea virus with mutations, the mutated mRNA sequence has higher expression and better immunostimulatory effect, the expression is increased by 10 times, and excellent immunization effect is achieved in mice and piglets; the trivalent combined vaccine has broad-spectrum immunization effect and can reduce diarrhea of piglets, and the immunization effect is far superior to that of commercial vaccines tested in experiments. The mutated mRNA vaccine has outstanding progress and is suitable for popularization and application.

The invention provides a composite vaccine adjuvant based on ergothioneine-sulfhydrylated polypeptide and a vaccine composition and application thereof, and belongs to the crossing field of biotechnology and medicine (including veterinary use). The composite vaccine adjuvant comprises a component A and a component B, wherein the component A comprises the following components in percentage by weight: 0.5%-5.0% of L-ergothioneine, 0.3%-2.0% of (Gly-SH) n oligopeptide, 2.0%-8.0% of aluminum hydroxide and / or aluminum phosphate, 1.0%-3.0% of a targeting carrier, 5.5%-13.0% of a freeze-drying protective additive and the balance of a buffer solution; the component B is CpG ODN, and the final concentration of the component B is 10-25 mu g / mL. The composite vaccine adjuvant system integrates sulfhydrylation modification enhanced combination and multi-component synergistic immunization, can be used for inducing balanced Th1 / Th2 immune response of mammals (including human, pigs, cattle and the like) and birds (chicken, ducks and the like) to intracellular / extracellular pathogens, and can be adapted to subunit vaccines, inactivated vaccines, recombinant antigen vaccines and combined vaccines; meanwhile, healthy groups and immunosuppressive groups (young, stress substance and immunodeficient groups) are compatible.

The invention discloses a polypeptide combination vaccine as well as a preparation method and application thereof. The polypeptide combination vaccine comprises A02 and A24 polypeptides, a vaccine adjuvant cyclic diguanylate (CDGSF) and a linker L for coupling the polypeptides with the CDGSF. The polypeptide vaccine has good tumor inhibition activity.

The invention belongs to the technical field of biological medicine, and particularly relates to a mixed vaccine for expressing Brucella multiple antigens and a preparation method and application thereof, and the mixed vaccine is obtained by encapsulating active mRNA by lipid nanoparticles; the nucleotide sequence of the active mRNA is at least one of SEQ ID NO. 1 to SEQ ID NO. 8. The mixed vaccine is prepared by independently encapsulating mRNA (messenger Ribonucleic Acid) of eight key antigens of Brucella by using LNP (Lipoprotein Natriuretic Peptide). According to the mixed vaccine, the problem of antigen competition is avoided, the mixed vaccine can be efficiently delivered to an immune system, and each antigen can initiate balanced immune response.

The invention relates to the technical field of veterinary biological products, in particular to a preparation method of a mixed vaccine for combined immunization of foot-and-mouth disease and other pig live vaccines and an immunization method. The preparation method of the mixed vaccine for combined immunization of the foot-and-mouth disease and other pig live vaccines comprises the following steps: heating the foot-and-mouth disease inactivated vaccine to 20-25 DEG C, using the foot-and-mouth disease inactivated vaccine as a dilution matrix, dissolving the pig live vaccines needing combined immunization, and uniformly mixing to form a stable emulsion, thereby obtaining the mixed vaccine. According to the mixed vaccine disclosed by the invention, the immunological injection times are reduced, and the stress and cross infection risks of pigs are reduced; it is ensured that the titer of antibodies corresponding to all vaccines after combined immunization reaches the protection standard, and the immunization effect is better than that of independent immunization or simple mixed immunization; the method is simple to operate, low in cost and suitable for popularization and application in the aspect of enhancing immunity in large-scale pig farms.

The utility model discloses an efficient mixing and stirring device for detecting a vaccine adjuvant preparation, and belongs to the technical field of vaccine processing. The first stirring assembly, the second stirring assembly and the third stirring assembly are sequentially arranged on the stirring shaft, a vertical rod of the first stirring assembly is arranged on the side, close to the second stirring assembly, of the first stirring assembly, and the second stirring assembly and the stirring shaft form an inclined angle a in the rotating direction; the first transverse rods of the third stirring assemblies and the stirring shaft form inclination angles b, and the inclination angles b of the multiple third stirring assemblies are different. A plurality of groups of stirring assemblies are arranged on the stirring shaft of the stirring device, so that the mixed vaccine preparation adjuvant is fully stirred in a layered manner, and vertical rods are arranged on the stirring assemblies to form different angles, so that the mixed vaccine preparation adjuvant is circularly stirred from top to bottom; the situation that the uniformly stirred vaccine preparation adjuvant stands still in the mixing tank body and is separated, and then the stirring effect is influenced is avoided.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a combined vaccine of a porcine deltacoronavirus antigen. The combined vaccine comprises an antigen and a pharmaceutically acceptable carrier, the antigen comprises an immune effective dose of porcine deltacoronavirus PDCoV HN02 or a culture thereof, the porcine deltacoronavirus PDCoV HN02 is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: V202441, the preservation address is Wuhan University, Wuhan, China, and the preservation date is March 28, 2024. The invention also relates to an application of the porcine delta coronavirus PDCoV HN02 or the culture of the porcine delta coronavirus PDCoV HN02 in a combined vaccine. After pigs are immunized by the combined vaccine, clinical symptoms caused by mixed infection can be relieved, and effective protection is provided for the pigs.

The present disclosure provides a tFiber protein fragment of avian egg drop syndrome virus, wherein the gene that encoded the tFiber protein fragment of avian egg drop syndrome virus has a nucleotide sequence shown in SEQ ID NO. 2 or a degenerate sequence thereof, and a vaccine composition prepared from the protein fragment. The fragment has good immunogenicity and is capable of preparing combined vaccine with various antigens, producing complete protection to the chickens and ducks.

The application discloses a combined vaccine for preventing hand-foot-mouth disease, which comprises inactivated enterovirus 71 virus, and inactivated coxsackievirus A 16 virus, coxsackievirus A 10 virus and coxsackievirus A 6 virus. The application also discloses a method for preparing the combined vaccine, and the prepared vaccine has good adsorption effect and stability. The multiple antigens do not interfere with antigenicity and immunization effect of each other after immunizing an object, and have good immunogenicity and safety. The use of the combined vaccine can obviously simplify a vaccine inoculation procedure, improve inoculation efficiency and reduce cost.

The invention relates to a HPV vaccine composition and a dengue vaccine composition for use in a method of preventing an HPV-associated disease and dengue disease in a subject or in a subject population, the method comprising concomitantly administering the HPV vaccine composition and the dengue vaccine composition, wherein the dengue vaccine composition is a tetravalent dengue composition comprising live, attenuated DENV-1, DENV-2, DENV-3 and DENV-4 strains and wherein the method provides combined vaccine efficacy against all four serotypes of the dengue virus and non-inferiority of the immune respone to the HPV vaccine composition compared to a mono-administratrion of the HPV vaccine composition.

The present invention provides an immunogenic composition and a three-component pertussis, diphtheria, and tetanus combined vaccine, particularly a diphtheria, pertussis, and tetanus vaccine with enhanced immune response. The immunogenic composition and vaccine of the present invention contain a specially selected bialuminum-based adjuvant. The resulting combined vaccine is capable of inducing a robust immune response while ensuring vaccine safety.

The application provides a monoclonal antibody 4E3 and a monoclonal antibody 4D5 which specifically bind to a SEA type O foot-and-mouth disease virus, and a double-antibody sandwich kit with the monoclonal antibody 4E3 as a coating antibody and the monoclonal antibody 4D5 as an enzyme-labeled antibody; the kit can quantitatively detect the content of the SEA type O foot-and-mouth disease virus-like particles, and can detect the content of the SEA type O foot-and-mouth disease virus-like particles in a single vaccine, a multivalent vaccine or a combined vaccine; and can quantitatively detect the content of antigens in a semi-finished vaccine or a finished vaccine.

The application discloses a tumor antigen for glioma and application thereof, and belongs to the field of biomedical technology. Based on a novel curative effect marker URGCP, HEATR1 and HCMV screening and verification, effective immunogenic peptide segments are obtained, a trivalent vaccine is prepared, and the trivalent vaccine is verified to enhance the antigen presentation ability of DCs in vitro. After overexpression of HCMV and exploration of a suitable radiation dose, in-vivo experiments are used to verify that the trivalent mixed vaccine promotes DC homing, lymph node activation, tumor-specific T cell generation, establishment of humoral immunity and memory immunity. Finally, a preventive model and a therapeutic model are used to verify that the universal DC vaccine can inhibit tumor progression and has good safety.

The present disclosure provides a combined vaccine against human respiratory syncytial virus (RSV) infection and a method thereof for inducing immune response. The combined vaccine includes: a first composition including an immunologically effective dosage of a replication-deficient human adenovirus type 26 vector contains a nucleotide encoding an antigenic protein of RSV and a pharmaceutically acceptable vector; and a second composition including an immunologically effective dosage of a replication-deficient chimpanzee adenovirus type 63 vector contains a nucleotide encoding an antigenic protein of RSV and a pharmaceutically acceptable vector. The first composition is a primary immunization composition and the second composition is a booster immunization composition; or vice versa. In the present disclosure, the combined vaccine is used for inducing a protective immunity against RSV infection, and a method is provided for generating the protective immunity against RSV infection.

The invention discloses a tumor antigen for glioma and application thereof, and belongs to the technical field of biomedicine. Effective immunogenic peptide fragments are obtained through screening and verification on the basis of novel curative effect markers URGCP, HEATR1 and HCMV, the trivalent vaccine is prepared, and the antigen presentation capacity of DC is enhanced through in-vitro verification of the trivalent vaccine. After the HCMV is over-expressed and a proper radioactive ray irradiation dose is explored, in-vivo experiments are utilized to verify that the trivalent mixed vaccine promotes DC homing, lymph node activation, tumor specific T cell generation and establishment of humoral immunity and memory immunity. Finally, a prophylactic model and a therapeutic model verify that the universal DC vaccine can inhibit tumor progression and has good safety.